Navigation Links
Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
Date:10/22/2007

PASADENA, Calif., Oct. 22 /PRNewswire/ -- Maven Biotechnologies, LLC, an early stage biotechnology company developing a label-free multiplexing immunodiagnostic analysis system, today announced that the company will deliver a presentation at the BIOCOM Investor Conference in San Diego, California. Jeffrey C. Travis, Ph.D., Maven's President and COO, will present on Thursday, November 1, 2007 at 3:30 PM.

About Maven Biotechnologies

Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free Internal Reflection Ellipsometry) which is a complete diagnostics analysis system (instruments and disposables) that provides a next generation replacement measurement technology with significant cost benefits to the healthcare sector and technology improvements for the combined $15 B w/w immunodiagnostic markets. It offers the potential advantages of 50-75% reduced costs to both the diagnostics manufacturers and the clinical or pharma lab user. In addition, its breakthrough new way to measure immunodiagnostic tests more rapidly will positively impact point-of-care (POC) tests for emergency room screening (e.g. cardiac markers, drugs of abuse, etc.), at patient bedside, and in the O.R. Finally, it uniquely permits single to high density label-free multiplexing -- that is, when one to large numbers of tests per patient can be run at one time (e.g. tumor markers, autoimmune panels, etc.), greatly reducing costs for the patients, healthcare provider and importantly, the medical insurance industry. LFIRE(TM) is an enabling technology for more cost effective patient profiling of multiple tests for diagnosis, staging of disease and choice of targeted drug therapy, all key elements required for the medical industry's personalized medicine initiative. Most significantly, the market infrastructure for this technology already exists in the worldwide diagnostics and pharma industries and market penetration for this improved next generation, markedly cost effective, replacement measurement technology will be rapid. The Company is now planning development for the first commercial versions of LFIRE(TM), with planned market launch later in 2008.

http://www.mavenbiotech.com


'/>"/>
SOURCE Maven Biotechnologies, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):